bluuebunny/crossref_metadata_2025_split huggingface dataset:
Emergence of carbapenem-resistant
Pseudomonas aeruginosa
ST179 producing both IMP-16 and KPC-2: a case study of introduction from Peru to Spain
Authors: Viñes Joaquim , Lopera Carlos , Vergara Andrea , Roca Ignasi , Vila Jordi , Casals-Pascual Climent , Martínez José Antonio , García-Vidal Carolina , Soriano Alex , Pitart Cristina 
Published: May 2024

ABSTRACT

We describe four cases of a novel carbapenem-resistant
Pseudomonas aeruginosa
ST179 clone carrying the
bla
KPC-2
or
bla
KPC-35
gene together with
bla
IMP-16
, imported from Peru to Spain and isolated from leukemia patients. All isolates were multidrug-resistant but remained susceptible to fosfomycin, cefiderocol, and colistin. Whole-genome sequencing revealed that
bla
KPC-2
and
bla
KPC-35
were located in an IncP6 plasmid, whereas
bla
IMP-16
was in a chromosomal type 1 integron. This study highlights the global threat of multidrug-resistant
P. aeruginosa
clones and underscores the importance of monitoring and early detection of emerging resistance mechanisms to guide appropriate treatment strategies. The importation and spread of such clones emphasize the urgent need to implement strict infection control measures to prevent the dissemination of carbapenem-resistant bacteria.

IMPORTANCE

This is the first documented case of a
Pseudomonas aeruginosa
ST179 strain carrying the blaKPC-35 gene, and it represents the first report of a
P. aeruginosa
co-harboring blaIMP-16 and either blaKPC-2 or blaKPC-35, which wre imported from Peru to Spain, highlighting a threat due to the capacity of spreading carbapenem-resistance via plasmid conjugation.
Baseline clinical and MRI risk factors for hamstring reinjury showing the value of performing baseline MRI and delaying return to play: a multicentre, prospective cohort of 330 acute hamstring injuries
Authors: Zein Muhammad Ikhwan , Mokkenstorm Milo J K , Cardinale Marco , Holtzhausen Louis , Whiteley Rod , Moen Maarten H , Reurink Guus , Tol Johannes L 
Published: May 2024

ObjectivesStudies identifying clinical and MRI reinjury risk factors are limited by relatively small sample sizes. This study aimed to examine the association between baseline clinical and MRI findings with the incidence of hamstring reinjuries using a large multicentre dataset.MethodsWe merged data from four prospective studies (three randomised controlled trials and one ongoing prospective case series) from Qatar and the Netherlands. Inclusion criteria included patients with MRI-confirmed acute hamstring injuries (<7 days). We performed multivariable modified Poisson regression analysis to assess the association of baseline clinical and MRI data with hamstring reinjury incidence within 2 months and 12 months of follow-up.Results330 and 308 patients were included in 2 months (31 (9%) reinjuries) and 12 months (52 (17%) reinjuries) analyses, respectively. In the 2-month analysis, the presence of discomfort during the active knee extension test was associated with reinjury risk (adjusted risk ratio (ARR) 3.38; 95% CI 1.19 to 9.64). In the 12 months analysis, the time to return to play (RTP) (ARR 0.99; 95% CI 0.97 to 1.00), straight leg raise angle on the injured leg (ARR 0.98; 95% CI 0.96 to 1.00), the presence of discomfort during active knee extension test (ARR 2.52; 95% CI 1.10 to 5.78), the extent of oedema anteroposterior on MRI (ARR 0.74; 95% CI 0.57 to 0.96) and myotendinous junction (MTJ) involvement on MRI (ARR 3.10; 95% CI 1.39 to 6.93) were independently associated with hamstring reinjury.ConclusionsTwo clinical findings (the presence of discomfort during active knee extension test, lower straight leg raise angle on the injured leg), two MRI findings (less anteroposterior oedema, MTJ involvement) and shorter time to RTP were independently associated with increased hamstring reinjury risk. These findings may assist the clinician to identify patients at increased reinjury risk following acute hamstring injury.Trial registration numbersNCT01812564;NCT02104258; NL2643; NL55671.018.16
Outrunning the grim reaper: longevity of the first 200 sub-4 min mile male runners
Authors: Foulkes Stephen , Hewitt Dean , Skow Rachel , Dover Douglas , Kaul Padma , La Gerche André , Haykowsky Mark 
Published: May 2024

ObjectivesTo determine the impact of running a sub-4 min mile on longevity. It was hypothesised that there would be an increase in longevity for runners who successfully completed a sub-4 min mile compared with the general population.MethodsAs part of this retrospective cohort study, the Sub-4 Alphabetic Register was used to extract the first 200 athletes to run a sub-4 min mile. Each runner’s date of birth, date of their first successful mile attempt, current age (if alive) or age at death was compared with the United Nations Life Tables to determine the difference in each runner’s current age or age at death with their country of origin-specific life expectancy.ResultsOf the first 200 sub-4 min mile runners (100% male), 60 were dead (30%) and 140 were still alive. Sub-4 min mile runners lived an average of 4.7 years beyond their predicted life expectancy (95% CI 4.7 to 4.8). When accounting for the decade of completion (1950s, 1960s or 1970s), the longevity benefits were 9.2 years (n=22; 95% CI 8.3 to 10.1), 5.5 years (n=88; 95% CI 5.3 to 5.7) and 2.9 years (n=90; 95% CI 2.7 to 3.1), respectively.ConclusionSub-4 min mile runners have increased longevity compared with the general population, thereby challenging the notion that extreme endurance exercise may be detrimental to longevity.
Glucose levels measured with continuous glucose monitoring in uncomplicated pregnancies
Authors: Carlson Anders L , Beck Roy W , Li Zoey , Norton Elizabeth , Bergenstal Richard M , Johnson Mary , Dunnigan Sean , Banfield Matthew , Krumwiede Katie J , Sibayan Judy R , Calhoun Peter , Durnwald Celeste 
Published: May 2024

IntroductionTo characterize glucose levels during uncomplicated pregnancies, defined as pregnancy with a hemoglobin A1c <5.7% (<39 mmol/mol) in early pregnancy, and without a large-for-gestational-age birth, hypertensive disorders of pregnancy, or gestational diabetes mellitus (ie, abnormal oral glucose tolerance test).Research design and methodsTwo sites enrolled 937 pregnant individuals aged 18 years and older prior to reaching 17 gestational weeks; 413 had an uncomplicated pregnancy (mean±SD body mass index (BMI) of 25.3±5.0 kg/m2) and wore Dexcom G6 continuous glucose monitoring (CGM) devices throughout the observed gestational period. Mealtimes were voluntarily recorded. Glycemic levels during gestation were characterized using CGM-measured glycemic metrics.ResultsParticipants wore CGM for a median of 123 days each. Glucose levels were nearly stable throughout all three trimesters in uncomplicated pregnancies. Overall mean±SD glucose during gestation was 98±7 mg/dL (5.4±0.4 mmol/L), median per cent time 63–120 mg/dL (3.5–6.7 mmol/L) was 86% (IQR: 82–89%), median per cent time <63 mg/dL (3.5 mmol/L) was 1.8%, median per cent time >120 mg/dL (6.7 mmol/L) was 11%, and median per cent time >140 mg/dL (7.8 mmol/L) was 2.5%. Mean post-prandial peak glucose was 126±22 mg/dL (7.0±1.2 mmol/L), and mean post-prandial glycemic excursion was 36±22 mg/dL (2.0±1.2 mmol/L). Higher mean glucose levels were low to moderately associated with pregnant individuals with higher BMIs (103±6 mg/dL (5.7±0.3 mmol/L) for BMI ≥30.0 kg/m2vs 96±7 mg/dL (5.3±0.4 mmol/L) for BMI 18.5–<25 kg/m2, r=0.35).ConclusionsMean glucose levels and time 63–120 mg/dL (3.5–6.7 mmol/L) remained nearly stable throughout pregnancy and values above 140 mg/dL (7.8 mmol/L) were rare. Mean glucose levels in pregnancy trend higher as BMI increases into the overweight/obesity range. The glycemic metrics reported during uncomplicated pregnancies represent treatment targets for pregnant individuals.
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
Authors: Naing Aung , Papadopoulos Kyriakos P , Pishvaian Michael J , Rahma Osama , Hanna Glenn J , Garralda Elena , Saavedra Omar , Gogov Sven , Kallender Howard , Cheng LuLu , Smith Michael , Chen Xuejun , Kuriakose Emil , Bauer Todd 
Published: May 2024

ObjectiveThe arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.Methods and analysisIn this non-randomised, open-label, three-part phase 1 study, INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks. Dose expansion was conducted in tumour-type cohorts (with or without prior anti−PD-1/PD-L1 (programmed death protein 1/programmed death ligand 1) therapy).ResultsA total of 107 patients received INCB001158 50–150 mg two times per day as monotherapy, and 153 patients, including 6 with moderate renal impairment, received INCB001158 50–100 mg two times per day combined with pembrolizumab. INCB001158 exposure was similar between groups (median, 56 days (monotherapy); 84 days (combination)). 49 patients (45.8%) on monotherapy and 76 (51.7%) on combination therapy experienced grade ≥3 treatment-emergent adverse events (AEs). The most common INCB001158-related AEs were fatigue (n=10/107 (9.3%)) and nausea (n=10/107 (9.3%)) with monotherapy and diarrhoea (n=24/147 (16.3%)) and fatigue (n=22/147 (15.0%)) with combination therapy. The highest response rate was seen in the anti–PD-1/PD-L1–naive combination therapy group with head/neck squamous cell carcinoma (overall response rate, 19.2%; 4/26 partial responses, 1/26 complete response). Consistent with arginase inhibition activity, plasma arginine dose-dependently increased. Arginase 1 expression in the tumour microenvironment did not correlate with response.ConclusionsINCB001158 was generally well tolerated. Response rates did not exceed background for given tumour types despite demonstrable pharmacodynamic activity. Overall, the limited antitumour activity of arginase inhibition observed suggests that the role of arginine depletion in cancer is multifaceted.Trial registration numberNCT02903914.
SurLym trial: study protocol for a multicentre pragmatic randomised controlled trial on the added value of reconstructive lymphatic surgery to decongestive lymphatic therapy for the treatment of lymphoedema
Authors: Devoogdt Nele , De Vrieze Tessa , Heroes An-Kathleen , Bechter-Hugl Beate , Fieuws Steffen , Godderis Lode , Segers Katarina , Maleux Geert , Deltombe Thierry , Frippiat Jacqueline , Servaes Maxime , Berners Aline , Fosseprez Philippe , Krug Bruno , Kayser Francoise , Falticeanu Ana , Randon Caren , Monten Chris , Van Landuyt Koen , De Pypere Bernard , Degraeve Liesl , Decorte Tina , De Schryver Mieke , Van Besien Vickie , Devos Daniel , Suominen Sinikka , Ayala Jaume Masia , Pons Gemma , Fourneau Inge , Thomis Sarah 
Published: May 2024

IntroductionLymphoedema is a chronic condition caused by lymphatic insufficiency. It leads to swelling of the limb/midline region and an increased risk of infection. Lymphoedema is often associated with mental and physical problems limiting quality of life. The first choice of treatment is a conservative treatment, consisting of exercises, skin care, lymph drainage and compression. Reconstructive lymphatic surgery is also often performed, that is, lymphovenous anastomoses, lymph node transfer or a combination. However, robust evidence on the effectiveness of reconstructive lymphatic surgery is missing. Therefore, the objective of this trial is to investigate the added value of reconstructive lymphatic surgery to the conservative treatment in patients with lymphoedema.Methods and analysisA multicentre randomised controlled and pragmatic trial was started in March 2022 in three Belgian university hospitals. 90 patients with arm lymphoedema and 90 patients with leg lymphoedema will be included. All patients are randomised between conservative treatment alone (control group) or conservative treatment with reconstructive lymphatic surgery (intervention group). Assessments are performed at baseline and at 1, 3, 6, 12, 18, 24 and 36 months. The primary outcome is lymphoedema-specific quality of life at 18 months. Key secondary outcomes are limb volume and duration of wearing the compression garment at 18 months. The approach of reconstructive lymphatic surgery is based on presurgical investigations including clinical examination, lymphofluoroscopy, lymphoscintigraphy, lymph MRI or CT angiography (if needed). All patients receive conservative treatment during 36 months, which is applied by the patient’s own physical therapist and by the patient self. From months 7 to 12, the hours a day of wearing the compression garment are gradually decreased.Ethics and disseminationThe study has been approved by the ethical committees of University Hospitals Leuven, Ghent University Hospital and CHU UCL Namur. Results will be disseminated via peer-reviewed journals and presentations.Trial registration numberNCT05064176
Risk communication in cataract surgery
Authors: Martinez Diana Lucia , Ahmed Iqbal Ike K. , Schlenker Matthew B. 
Published: May 2024

PurposeRisk communication is an integral aspect of shared decision-making and evidence-based patient choice. There is currently no recommended way of communicating risks and benefits of cataract surgery to patients. This study aims to investigate whether the way this information is presented influences patients’ perception of how risky surgery will be.Methods and analysisTwo-arm parallel randomised study and patients referred for cataract surgery were assigned to receive information framed either positively (99% chance of no adverse effects) or negatively (1% chance of adverse effects). Subsequently, patients rated their perceived risk of experiencing surgical side effects on a 1–6 scale.ResultsThis study included 100 patients, 50 in each study group. Median (IQR) risk perception was 2 (1–2) in the positive framing group and 3 (1–3) in the negative framing group (p<0.0001). Risk framing was the only factor that was significant in risk perception, with no differences found by other patient clinical or demographic characteristics.ConclusionPatients who received positive framing reported lower risk scores for cataract surgery than patients who received negative framing. Patient factors were not identified as significant determinants in patients’ perceived risk. Larger longitudinal studies are warranted to further investigate.
On dark energy effects on the accretion physics around a Kiselev spinning black hole
Authors: Pugliese D. , Stuchlík Z. 
Published: May 2024

AbstractKiselev metric in the static and rotating form is widely used to test different aspects of the dark energy (DE) effects. We consider a DE Kiselev spacetime, predicting the reduction to the Kerr black hole (BH) solution under suitable conditions on the DE parameters and in this frame we study the effects of the dark energy on BHs and disks accretion. Elaborating a close comparison with the limiting vacuum Kerr spacetime, we focus on thick accretion disks around the central BH in the Kiselev solution, both co-rotating and counter-rotating with respect the central BH. We examine different aspects of BH accretion energetics by focusing on quantities related to the accretion rates and cusp luminosity, when considered the DE presence, related to the pure Kerr central BH. Our findings show that in these conditions heavy divergences with respect to the vacuum case are expected for the DE metrics. A known effect of the Kiselev metric is to lead to a false estimation the BH spin, we confirm this characteristic from the fluids dynamics analysis. Remarkably our results show that DE is affecting differently the accretion physics, and particularly the accretion rate, according to the fluid rotation orientation with respect to the central spinning attractor, leading in some cases to an under-estimation of the BH spin mass ratio. These contrasting aspects emerging in dependence on the fluids rotational orientation can be a distinguishing general DE feature which could lead to a revised observational paradigm where DE existence is considered.
Characterisation of the neutron sources in use at STUK SSDL through a new transfer instrument with spectrometric capabilities
Authors: Bedogni R. , Russo L. , Calamida A. , Campoy A. I. Castro , Caballero-Pacheco M. A. , Dashdondog D. , Mafucci E. , Monti V. , Costa M. , Pietropaolo A. , Gomez-Ros J. M. , Toroi P. , Huikari J. 
Published: May 2024

AbstractCharacterising neutron sources for calibration or generic testing purposes is a complex task, as the neutron spectrum may depend, to some extent, on the construction characteristics of the source. Bonner spheres (BS) are the traditional spectrometric transfer instruments, but they are very sensitive to room scatter and required measurements are highly time consuming. The recently developed NCT-WES device, belonging to the family of the Single Moderator Neutron Spectrometers, has been proposed as a convenient alternative to BS. This work presents the results of a demonstration campaign organised at the STUK neutron metrology laboratory (Finland) in July 2023, where the spectra from two 252Cf and two 241Am-Be sources were determined. For the 241Am-Be sources, the results were compared to the spectra of two categories recently introduced by ISO 8529-1. Based on the results it was concluded that the “large” source category is an appropriate selection for STUK sources. The campaign also proved the operational advantages of NCT-WES as spectrometric transfer instrument.
Radiation attenuation properties of transparent aluminum oxynitride: a comprehensive study
Authors: Yıldırım Aydın 
Published: May 2024

AbstractThe investigation of radiation-durable materials with outstanding gamma shielding capabilities and lead-free alternatives remains a compelling area of research. This study fills a critical gap by exploring, for the first time, the radiation attenuation properties of the novel material aluminum oxynitride (AlON) and its shielding mechanism. Utilizing the XCOM database and Geant4 Monte Carlo simulation toolkit, we systematically examined AlON’s linear attenuation coefficient, mass attenuation coefficient, half-value layer, tenth-value layer, mean-free path, effective atomic number, and effective electron density. Comparing AlON to traditional shielding materials and glasses, including both lead-containing and lead-free compositions, our study suggests its superiority over concrete and lead-free glasses. At higher energies, AlON demonstrates comparability with lead-doped materials. These findings contribute valuable insights into the potential applications of AlON across diverse radiation shielding contexts. This research provides a foundational understanding of AlON’s radiation attenuation capabilities, paving the way for future exploration and practical applications in the field of gamma shielding.
Off-resonance electronic detection and cooling of ions in a Penning trap
Authors: Ringleb Stefan , Kiffer Markus , Vogel Manuel , Stöhlker Thomas 
Published: May 2024

AbstractWe present a non-destructive electronic detector for stored charged particles in a Penning trap that uses a symmetric electrode arrangement for signal pickup and a resonator without tap. This system has advantageous off-resonance features which are demonstrated by means of detection and cooling measurements with highly charged ions in a cryogenic Penning trap. In particular, it allows for particle detection across a wide range of frequencies that is not concomitant with cooling and offers a novel way to tune a trap with the help of non-destructive measurements on large particle ensembles.
Multiplicity and concentration of solutions for Kirchhoff equations with exponential growth
Authors: Sun Xueqi , Fu Yongqiang , Liang Sihua 
Published: May 2024

In this paper, we deal with fractional [Formula: see text]-Laplace Kirchhoff equations with exponential growth of the form [Formula: see text] where [Formula: see text] is a positive parameter, [Formula: see text], [Formula: see text] and [Formula: see text]. Under some appropriate conditions for the nonlinear function [Formula: see text] and potential function [Formula: see text], and with the help of penalization method and Lyusternik–Schnirelmann theory, we establish the existence, multiplicity and concentration of solutions. To some extent, we fill in the gaps in [W. Chen and H. Pan, Multiplicity and concentration of solutions for a fractional [Formula: see text]-Kirchhoff type equation, Discrete Contin. Dyn. Syst. 43 (2023) 2576–2607; G. Figueiredo and J. Santos, Multiplicity and concentration behavior of positive solutions for a Schrödinger–Kirchhoff type problem via penalization method, ESAIM Control Optim. Calc. Var. 20 (2014) 389–415; X. He and W. Zou, Existence and concentration behavior of positive solutions for a Kirchhoff equation in [Formula: see text] J. Differential Equations 252 (2012) 1813–1834; J. Wang, L. Tian, J. Xu and F. Zhang, Multiplicity and concentration of positive solutions for a Kirchhoff type problem with critical growth, J. Differential Equations 253 (2012) 2314–2351].
Comparison of Long-Term Healthcare Cost and Utilisation of Nonoperative and Surgical Management of Thumb CMC Arthritis
Authors: YOON Alfred P. , WU Hao , CHUNG William T. , WANG Lu , CHUNG Kevin C. 
Published: May 2024

Background: Thumb carpometacarpal joint (CMC) osteoarthritis is the most symptomatic hand arthritis but the long-term healthcare burden for managing this condition is unknown. We sought to compare total healthcare cost and utilisation for operative and nonoperative treatments of thumb CMC arthritis. Methods: We conducted a retrospective longitudinal analysis using a large nationwide insurance claims database. A total of 18,705 patients underwent CMC arthroplasty (trapeziectomy with or without ligament reconstruction tendon interposition) or steroid injections between 1 October 2015 and 31 December 2018. Primary outcomes, healthcare utilisation and costs were measured from 1 year pre-intervention to 3 years post-intervention. Generalised linear mixed effect models adjusted for potentially confounding factors such as the Elixhauser comorbidity score with propensity score matching were applied to evaluate the association between the primary outcomes and treatment type. Results: A total of 13,646 patients underwent treatment through steroid injections, and 5,059 patients underwent CMC arthroplasty. At 1 year preoperatively, the surgery group required $635 more healthcare costs (95% CI [594.28, 675.27]; p < 0.001) and consumed 42% more healthcare utilisation (95% CI [1.38, 1.46]; p < 0.0001) than the steroid injection group. At 3 years postoperatively, the surgery group required $846 less healthcare costs (95% CI [−883.07, −808.51], p < 0.0001) and had 51% less utilisation (95% CI [0.49, 0.53]; p < 0.0001) annually. Cumulatively over 3 years, the surgical group on average was $4,204 costlier than its counterpart secondary to surgical costs. Conclusions: CMC arthritis treatment incurs high healthcare cost and utilisation independent of other medical comorbidities. At 3 years postoperatively, the annual healthcare cost and utilisation for surgical patients were less than those for patients who underwent conservative management, but this difference was insufficient to offset the initial surgical cost. Level of Evidence: Level III (Therapeutic)